Biogen, Eisai’s lecanemab gets Alzheimer’s nod, but how successful it will be is uncertain

Rate this post

agrobacter/iStock via Getty Images

The US FDA on Friday granted accelerated approval to Biogen (NASDAQ:BIIB) and Eisai’s (OTCPK:ESALY) Leqembi (lecanemab), just the second biologic medicine ever approved for Alzheimer’s disease.

The therapy is expected to become available around the

Authore – Abhi bhardwaj

Hello friends, my Abhi Bhardwaj I am the owner of and I am also a student. recently I just completed my graduation I am doing blogging since 2020 I love to write and always love exploring, and sharing knowledge with others that is why I started this blog basically this blog is related to us stock market, real estate, insurance, crypto, finance and tax if you have any qouri then please don't be shy

Sharing Is Caring:

Leave a Comment